Intec Pharma Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

NTEC

IL0011177958

Delayed TEL AVIV STOCK EXCHANGE 5-day change 1st Jan Change
- ILa -.--% Intraday chart for Intec Pharma Ltd -0.67% -16.62%
Sales 2024 * - Sales 2025 * - Capitalization 21.52M 8.09B
Net income 2024 * -21M -7.89B Net income 2025 * -24M -9.02B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.26 x
P/E ratio 2025 *
-1.77 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Top Premarket Gainers MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Gainers MT
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial CI
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20 CI
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20 CI
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 CI
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023 CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
INDAPTUS THERAPEUTICS SHARES UP 11.4% AFTER POSITIVE PRE-CLINIC… RE
Indaptus Therapeutics, Inc. Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at American Association for Cancer Research Conference 2023 CI
More news
Managers TitleAgeSince
Founder 68 21-02-23
Chief Executive Officer 57 21-08-02
Director of Finance/CFO 48 21-06-30
Members of the board TitleAgeSince
Director/Board Member 58 21-08-02
Chief Executive Officer 57 21-08-02
Director/Board Member 61 23-01-12
More insiders
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Sector
-
More about the company